Possis XMI catheter
This article was originally published in The Gray Sheet
Executive Summary
FDA market go-ahead is received for the 4 Fr catheter for removing blood clots from native coronary arteries and coronary bypass grafts. Used with the Minneapolis firm's AngioJet Rheolytic thrombectomy system, the XMI represents the first coronary technological upgrade since March 1999 and includes a lower profile and reduced bleeding risk at the access site, the firm says. The catheter was released for peripheral use in April...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.